Fuyou Life's organoid drug sensitivities are more precise and effective
Rich and Excellent Life
A domestic high-tech enterprise focused on organoid technology R&D, translation, and clinical application, centered on organoid culture technology, focusing on precise tumor drug sensitivity screening, building a complete innovative system from basic research and technology development to clinical diagnosis and treatment, providing full-process, standardized solutions for personalized cancer treatment. Relying on top-tier scientific research resources and deep integration of industry, academia, and research, the company has achieved remarkable results in building innovation platforms.
In 2025, it was approved as a key academician workstation in Jinan, jointly initiated the establishment of the National Yangtze River Delta (G35) Organoid Industry Innovation Alliance with Fudan University and Qidong Fudan Medical Innovation Research Institute, serving as the alliance's secretary-general, leading collaborative innovation and standards development in the regional organoid industry; It has successively collaborated with the Beijing Institute of Neurosurgery and Fudan University School of Basic Medical Sciences to collaborate on organoid research, tackling key technologies such as efficient organoid construction and precise drug sensitivity prediction.
In core technologies and product R&D, Fuyou Life insists on independent innovation, building a full-chain self-developed product matrix and forming an integrated solution covering sample processing—organoid construction—drug susceptibility screening—result analysis, achieving standardized processes, convenient operation, and precise results. At the same time, the company has built a multi-cancer high-throughput organoid drug susceptibility screening database, integrating real-world clinical data and drug susceptibility models to provide reliable data support for formulating personalized drug regimens, effectively improving tumor treatment effectiveness, extending patient survival, and enhancing long-term quality of life.
Lung adenocarcinoma
Lung
adenocarcinoma
Laryngeal squamous cell carcinoma
Laryngeal squamous cell carcinoma
Esophageal squamous cell carcinoma
Esophageal squamous cell carcinoma
Hemangiomas
Cavernous hemangioma
Brain glioma
Gliomas
Liver cancer
Hepatocellular carcinoma
Honors and qualifications
Every honor serves as a motivation, driving us to continuously push boundaries and create service value
Clinical medicine, AI-driven digitalization, PhD student
Executive Director of the Chinese Association of Traditional Chinese Medicine; Secretary-General of the National (G35) Organoid Industry Innovation Alliance; Entrepreneurship mentor at the Qidong Medical Innovation Research Institute of Fudan University, Shanghai; Deputy Director of the Organoid Industry Professional Committee of the Shandong Pharmaceutical Industry Association Secretary-General of the Organoid and Regenerative Medicine Branch of the Shandong Medical Ethics Society Expert in the Shandong Provincial Science and Technology Expert Database; Deeply engaged in organoid R&D, tumor drug susceptibility detection and clinical translation, with multiple patents and scientific research achievements; He also serves as a graduate advisor at multiple universities, maintaining long-term collaboration between universities and research institutes to carry out industry-university-research work. He led the construction of the Jinan Organoid and Gene Engineering Research Center and Key Laboratory, obtained 9 product registration certificates and 26 related patents, and achieved the transformation and mass production of multiple technologies in these areas.